Observational studyMedicine2025
Factors influencing hospital length of stay in febrile neutropenia: A retrospective cohort study of Turkish patients with solid tumors.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early clinical determinants of adverse outcomes in paediatric febrile neutropenia: a prospective cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febrile neutropenia (FN) is a severe complication of chemotherapy, associated with substantial mortality and financial burden. The purpose of this study was to assess the association between hospital length of stay (LOS), supportive therapies, and antibiotic regimens in patients with FN, with a specific focus on the Turkish population. Eighty adult patients with solid tumors were enrolled. Patients received empirical antibiotic therapy within 2 hours of presentation. Data were collected on clinical and demographic variables, including LOS, fever duration, Multinational Association of Supportive Care in Cancer Risk Index scores, and laboratory parameters. The mean hospital LOS was 6.09 ± 3.62 days. Sulperazon use was significantly associated with a shorter LOS compared to meronem and tazocin (P < .001). Patients receiving filgrastim had a longer LOS compared to those who did not (P = .042). Correlation analysis revealed strong positive associations between LOS and febrile days (R = 0.624, P < .001), febrile days during hospitalization (R = 0.711, P < .001), and filgrastim administration days (R = 0.722, P < .001). Multivariate analysis confirmed that sulperazon use reduced LOS by 1.271 days (P = .048), while prolonged filgrastim use was linked to longer stays (P < .001). These findings highlight the critical role of antibiotic selection and supportive care in managing hospitalization duration for patients with FN. The combination of certain treatments and antibiotics plays a significant role in determining the duration of hospital stays, highlighting factors to consider in patient management and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.